Natco Pharma Q1 net declines 28% to ₹480 cr on pricing pressure in U.S.
The Hindu
Natco Pharma's Q1 net profit drops 28% due to U.S. market pricing pressure, higher R&D costs, with revenue decline.
More Related News

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












